Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

PubWeight™: 10.71‹?› | Rank: Top 0.1%

🔗 View Article (PMC 166236)

Published in Proc Natl Acad Sci U S A on June 25, 2003

Authors

Giao Q Phan1, James C Yang, Richard M Sherry, Patrick Hwu, Suzanne L Topalian, Douglas J Schwartzentruber, Nicholas P Restifo, Leah R Haworth, Claudia A Seipp, Linda J Freezer, Kathleen E Morton, Sharon A Mavroukakis, Paul H Duray, Seth M Steinberg, James P Allison, Thomas A Davis, Steven A Rosenberg

Author Affiliations

1: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Articles citing this

(truncated to the top 100)

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72

Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40

The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 6.84

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18

Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43

A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25

Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25

Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53

Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther (2005) 3.49

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 2.95

Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med (2005) 2.51

From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46

Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28

PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol (2009) 2.14

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07

Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother (2005) 2.01

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res (2009) 1.77

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun (2008) 1.75

SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74

The B7 family of immune-regulatory ligands. Genome Biol (2005) 1.74

Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72

Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66

CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66

Monoclonal antibodies for cancer immunotherapy. Lancet (2009) 1.64

Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58

Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58

Harnessing the immune system to treat cancer. J Clin Invest (2007) 1.57

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56

Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. Cancer Biol Ther (2010) 1.55

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res (2010) 1.54

Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology (2006) 1.54

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48

The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47

Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood (2006) 1.45

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44

Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42

Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med (2005) 1.42

CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol (2009) 1.39

Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev (2009) 1.39

Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 1.37

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci (2008) 1.37

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res (2009) 1.37

Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36

Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36

Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer (2014) 1.35

Regulatory T cells and tumour immunity - observations in mice and men. Immunology (2007) 1.34

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33

CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010) 1.33

Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32

Immunology beats cancer: a blueprint for successful translation. Nat Immunol (2012) 1.32

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother (2008) 1.31

Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A (2011) 1.31

Articles cited by this

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 19.03

Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03

CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94

A cell culture model for T lymphocyte clonal anergy. Science (1990) 9.86

CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78

A theory of self-nonself discrimination. Science (1970) 7.99

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med (1999) 7.94

CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol (1998) 7.31

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10

A new member of the immunoglobulin superfamily--CTLA-4. Nature (1987) 5.10

CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97

Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol (2001) 4.58

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 3.73

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70

T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol (2001) 3.59

CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49

Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol (2000) 3.46

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol (1996) 3.40

Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89

Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol (1997) 2.81

Characterization of CTLA-4 structure and expression on human T cells. J Immunol (1993) 2.68

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med (2001) 2.46

Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (1998) 2.43

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother (2003) 2.10

Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol (1995) 1.78

CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol (2002) 1.78

Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol (1989) 1.72

Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol (1999) 1.67

Articles by these authors

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77

Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96

Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13

Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03

Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood (2011) 8.26

A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med (2011) 8.26

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76

A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83

Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01

Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63